Gastroesophageal Reflux Disease (GERD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Gastroesophageal Reflux Disease (GERD) Market Outlook

Thelansis’s “Gastroesophageal Reflux Disease (GERD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastroesophageal Reflux Disease (GERD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastroesophageal Reflux Disease (GERD) Overview

Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal condition that regurgitates stomach contents into the esophagus. Various mechanisms cause it, some intrinsic and some structural, to disrupt the barrier at the esophagogastric junction, exposing the esophagus to acidic gastric contents. Clinically, GERD commonly presents with symptoms like heartburn and regurgitation. However, it can manifest atypically with extra-esophageal symptoms such as chest pain, dental erosion, chronic cough, laryngitis, or asthma. GERD is categorized into three phenotypes based on endoscopic and histopathologic findings: non-erosive reflux disease (NERD), erosive esophagitis (EE), and Barrett’s esophagus (BE). Individuals with asthma face a higher risk of developing GERD. Asthma exacerbations can relax the lower esophageal sphincter, allowing stomach contents to reflux into the esophagus. Some asthma medications, particularly theophylline, may exacerbate reflux symptoms. Various diagnostic tests are available for GERD, including X-rays of the upper digestive system, endoscopy to visualize the esophagus, ambulatory acid (pH) monitoring to track esophageal acid levels and esophageal impedance testing to measure substance movement in the esophagus. Treatment options encompass lifestyle changes, medical management with antacids and drugs that reduce acid secretion, surgical interventions, and endoscopic therapies. Medical therapy includes the use of antacids, histamine (H2) receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and prokinetic agents. In the United States, two H2RAs (famotidine and cimetidine) are FDA-approved and available over-the-counter. Surgical management is considered for patients who do not respond to medical treatment, are noncompliant with it, experience side effects, have large hiatal hernias, or wish to discontinue long-term medical therapy.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Gastroesophageal Reflux Disease (GERD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034